IPO and Fundraising - The company completed its initial public offering (IPO) on January 16, 2025, raising total gross proceeds of $50,000,000 by selling 5,000,000 units at an offering price of $10.00 per unit[22]. - A total of $50,000,000 from the IPO and private placement was placed in a U.S.-based trust account for the benefit of public shareholders[24]. - The company has approximately $50,000,000 available for a business combination, which can be used for liquidity events, growth capital, or debt reduction[64]. - The company intends to use substantially all net proceeds from the IPO and private placement for its initial business combination and related expenses[151]. - The company may seek additional funds through private offerings of debt or equity securities to complete the initial business combination[67]. Business Combination Plans - The company entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd., and DRC Merger Inc. on June 30, 2025, and is focused on completing this proposed business combination[18]. - The company has 12 months from the closing of the offering to consummate an initial business combination, with the possibility of seeking shareholder approval for an extension[46]. - The initial business combination must involve target businesses with an aggregate fair market value of at least 80% of the balance in the trust account at the time of signing a definitive agreement[44]. - The company anticipates structuring the initial business combination to acquire 100% of the equity interests or assets of the target business, but may acquire less than 100% under certain conditions[47]. - If the company cannot complete the proposed business combination, it may continue to evaluate alternative business combination opportunities[48]. Financial Performance and Position - The company reported a net income of $690,218 for the year ended December 31, 2025, with operating expenses of $1,258,096 and income from marketable securities of $1,948,314[149]. - As of December 31, 2025, the company had $11,497 in cash and a working capital deficit of $556,173[152]. - The company has not generated any revenue to date and has incurred losses since inception due to formation and operating costs[147]. - The company has not paid any cash dividends and does not intend to do so prior to completing its initial business combination[133]. - The company has incurred approximately $14.9 million in redemptions from the trust account, reducing available funds for business combinations to about $10.40 per share[155]. Management and Governance - The management team has extensive experience in cross-border mergers and acquisitions, capital raising, and investment, which is expected to aid in identifying attractive acquisition targets[28]. - The management team believes that their ability to assess potential target companies will enhance the likelihood of successful public listings[31]. - The company has adopted a Code of Ethics applicable to its directors, officers, and employees, which will be available for review in public filings[204]. - The audit committee includes independent directors who are financially literate, with Mr. Chris Constable qualifying as an "audit committee financial expert"[195][198]. - The corporate governance and nominating committee oversees the selection of nominees for the board of directors, considering qualifications such as management experience and integrity[199][200]. Regulatory and Compliance Issues - The company does not currently hold any equity interest in any PRC company or operate any business in China, thus believes no permission is required from PRC governmental authorities for its operations or offerings[43]. - Any uncertainties regarding regulatory approvals from PRC authorities could materially affect the trading price of the company's securities[43]. - The company will comply with Regulation M and other federal securities laws for any private purchases made by its affiliates[86]. - The company will not complete the business combination if the cash required for redemptions exceeds the available cash in the trust account[97]. - The company is classified as an "emerging growth company" and will remain so until it has total annual gross revenue of at least $1.235 billion or meets other criteria[62]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem their shares at a per-share price equal to the aggregate amount in the trust account divided by the number of outstanding public shares[88]. - If shareholder approval is required, a public shareholder can only seek redemption rights for a maximum of 15% of the shares sold in the offering, referred to as "Excess Shares"[98]. - The tender offer for redemptions will remain open for at least 20 business days, and the company cannot complete the initial business combination until the tender offer period expires[91]. - Shareholders must exercise their redemption rights to receive funds from the trust account in connection with the initial business combination[116]. - The expected per-share redemption amount upon dissolution is approximately $10.00, subject to potential increases of up to $0.10 if the sponsor extends the business combination period[111]. Risks and Challenges - The company may face intense competition from other entities with similar business objectives, including blank check companies and private equity groups[49]. - There is a risk that the company may depend on the performance of a single business post-combination, limiting diversification[75]. - Management has raised substantial doubt about the Company's ability to continue as a going concern due to significant professional and transaction costs[154]. - The company’s board may face conflicts of interest in determining appropriate business combination targets due to affiliations with its Sponsor and directors[209]. - The company’s officers and directors owe fiduciary duties to the entities they are affiliated with, which may affect their obligations to the company[213].
Ribbon Acquisition Corp Unit Cons of 1 CL A + 1 Rt(RIBBU) - 2025 Q4 - Annual Report